Cancer Treatment Centers of America Expands Neuroendocrine Tumor Clinical Program with Innovative Therapy for Rare Disease
April 23, 2019 09:00 ET
|
Cancer Treatment Centers of America, Chicago
Chicago, Ill., April 23, 2019 (GLOBE NEWSWIRE) -- Physicians at Cancer Treatment Centers of America® (CTCA) Chicago have a new option in the fight against rare neuroendocrine tumors (NETs) with the...
RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.
January 22, 2019 10:00 ET
|
RadioMedix Inc.
Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.
January 09, 2019 01:00 ET
|
RadioMedix Inc.
Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical,...
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
November 13, 2018 10:00 ET
|
RadioMedix Inc.
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT ESMO 2018 CONGRESS
July 24, 2018 07:00 ET
|
Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, July 24, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing clinical trial of PV-10 for the treatment of...
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
January 10, 2018 05:00 ET
|
RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
June 22, 2017 16:00 ET
|
RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212
November 01, 2016 01:00 ET
|
RadioMedix Inc.
Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
October 20, 2016 02:30 ET
|
RadioMedix Inc.
Houston, TX, Oct. 20, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston,TX) is excited to announce the completion of the Phase I/II clinical trial of AminoMedix ™ proprietary formulation used...